Plenary Lecture
Hyo-Soo Kim
Resistin/Cap1 and PCSK9/Cap1 are the underlying mechanisms of metabolic syndrome
Kwang Kon Koh
Lipoprotein(a) and cardiovascular diseases: Past, Present, and Future
Deepak L. Bhatt
Residual Cardiovascular Risk – Now We Can REDUCE-IT!
Keynote Lecture
Arnold von Eckardstein
Search for novel HDL biomarkers
Soo Lim
Association of COVID-19 with cardiovascular and metabolic disorders
Invited Speaker
Toyoaki Murohara
Translational research: Adipose-derived regenerative cells for critical limb ischemia
Keiichi Fukuda
Development of Regenerative Therapy for Severe Heart Failure by Transplanting Human iPS Cell-derived Cardiomyocytes
Duck-chul Lee
Physical activity vs. physical fitness on cardiometabolic disease
Po-Hsun Huang
Inhibition of Trimethylamine N-oxide attenuates neointimal formation through reduction of the inflammasome in a mouse model of carotid artery ligation
Kai-Chien Yang
Targeting ER Protein TXNDC5 as a Novel Therapeutic Approach against Cardiac and Organ Fibrosis
Shin-ichiro Miura
Apolipoprotein A-I mimetics for the treatment of residual risk of cardiovascular disease
Yong Li
Diabetes and Heart Function
Neng Dai
Paradigm Shift in Anti-Diabetic Strategy: Focus on Cardiovascular Benefits
Dao-Quan Peng
New strategies to lipid modification to reduce residual ASCVD risk in 2021
Ichiro Sakuma
New PPARa agonist
Dong Hee Kim
Fatty Liver and CVD
